

Package of Care for People Living with HIV



ICAP

GLOBAL. HEALTH. ACTION.

Columbia University
Mailman School of Public Health

ICAP PACKAGE OF CARE

FOR PEOPLE LIVING WITH HIV

Background

The ICAP Model of Care is characterized by the delivery of comprehensive and integrated services along the HIV care continuum for adults, children, and pregnant women, with a focus on the family. Other elements of the model include a multidisciplinary team of providers; an emphasis on adherence and prevention; strong linkages between clinical services; and strong linkages with community resources. The ICAP Model of Care defines a Comprehensive Package of Care for adults and children living with HIV that should be considered in all ICAP-supported sites, and within the comprehensive package, a set of Core Interventions that should be prioritized and made available in all sites. The ICAP Package of Care encompasses the full continuum of HIV care from linkage of those found to be HIV positive to retention in care, prompt determination of eligibility for antiretroviral therapy (ART), and initiation of ART with provision of adherence support. “Care”, when used here, is defined as all clinical services, including ART, provided to people living with HIV (PLHIV). The evidence-based interventions included in the ICAP Package of Care have been selected based upon their impact on morbidity and mortality, with Core Interventions having the highest impact. Priority should be placed on implementing and achieving targets for the Core Interventions. Programs can also integrate additional interventions into HIV care delivery based upon their epidemiologic, health system, political, and financial context.

The purpose of this document is to describe the Core Interventions included in the ICAP Package of Care, as well as to summarize the evidence supporting them. This document can be used to guide newer programs in establishing HIV services, as well as to remind more established programs about the importance of ensuring high quality implementation of Core Interventions. The target audience includes clinical officers and other technical staff in ICAP country programs. Examples of standard operating procedures (SOPs) and tools developed and used by ICAP country programs to implement the Core Interventions included in the Package of Care are listed in the Appendix.

Comprehensive Package of Care

The Comprehensive Package of Care consists of a package of Core Interventions, as well as additional interventions that can be included according to context and resources.

Core Interventions

The minimum package of interventions that should be provided at all sites includes:

- HIV testing and counseling (HTC), including provider-initiated testing and counseling (PITC) and testing for partners and family members
- Linkage to HIV care of those testing positive from all entry points
- Cotrimoxazole prophylaxis for all eligible PLHIV
- Tuberculosis (TB) screening for PLHIV
 - For those with a positive screen, further diagnostic work-up and treatment
 - For those with a negative screen and/or diagnostic work-up, provision of isoniazid preventive therapy (IPT)
- Assessment of ART eligibility, with prompt ART initiation for all eligible PLHIV
 - WHO staging at every visit, including assessment and treatment of opportunistic illnesses
 - Monitoring of childhood growth and development
 - CD4 testing at enrollment in care and every six months thereafter
- Prevention of mother-to-child transmission of HIV

- Family planning services to prevent unintended pregnancies in women with HIV infection
- Provision of ART for all pregnant and breastfeeding women with HIV infection, with a preference for option B+, and ongoing care for HIV-infected mothers and exposed infants
- Medication monitoring and management
 - Monitoring of medication adherence with provision of adherence support
 - Monitoring for, and management of, medication-related side effects and toxicity
 - Monitoring for treatment response and treatment failure, with regimen adjustment as needed
- Monitoring and supporting retention in HIV care
- Access to laboratory testing for HIV diagnosis, determining ART eligibility, monitoring treatment response, and diagnosing TB
 - HIV diagnosis including rapid HIV testing and dried blood spot (DBS)-based HIV-1 DNA PCR for early infant diagnosis (EID)
 - CD4 testing for assessing ART eligibility and monitoring treatment response
 - Routine or targeted viral load monitoring to detect treatment failure
 - Microscopic or molecular TB diagnosis
- Psychosocial support

Additional Interventions

Depending on the epidemiologic, health system, political, and financial context, programs may choose to provide other interventions such as: hemoglobin, ALT and creatinine tests for monitoring medication-related toxicities; assessment and treatment of sexually transmitted infections (STI); hepatitis B surface antigen screening; Cryptococcal antigen screening; cervical cancer screening; malaria services; harm reduction services including opioid substitution therapy/medication assisted therapy; pain management; safe water and hygiene support; nutrition services; mental health services; end of life care; provision of childhood immunizations; and “adolescent-friendly” services and programming. These interventions will not be discussed in this document.

Core Interventions

HIV testing and counseling, including PITC and testing for partners and family members

HIV testing and counseling should be provided through PITC (opt-out testing) in addition to voluntary counseling and testing (VCT). At a minimum, PITC should be provided in TB, family planning, immunization, malnutrition and casualty services, antenatal care and inpatient settings, as well as where services are provided for key populations (including men who have sex with men, commercial sex workers, and people who inject drugs).

PLHIV should be asked about the HIV status of their partners and family members during HIV clinic visits; this information should be documented in the medical record and HIV testing should be encouraged and facilitated for family and household members including children with an unknown HIV status.

Programs may conduct other periodic HTC activities such as “family days” or community-based testing.

Data show that a greater proportion of inpatients undergo HTC when they are tested during hospitalization as opposed to deferring until after discharge.¹ PITC has also been shown to increase HIV case finding in a variety of settings including outpatient, STI, TB, and emergency services.² Male partner testing has been shown to improve retention in PMTCT programs,³⁻⁵ uptake of PMTCT interventions,^{4,6} and decreased risk of vertical transmission of HIV.⁷ Couples testing and counseling, when individuals in a sexual relationship receive HTC services together, can reduce self-reported risk behavior^{8,9} without increasing risk of overall

adverse events as compared to individual testing and counseling.¹⁰ Data indicate that HTC of children of PLHIV enrolled in care and treatment programs is very low, and rates of HIV infection among these children can be quite high.¹¹

Linkage to HIV care

Facilities offering HIV testing should have a SOP describing the process by which individuals testing HIV positive are linked to HIV care.

Linkage to care should be operationalized with a clear definition and should be documented for each individual testing HIV positive.

Strategies to increase linkage to HIV care include: formal referral systems using escorts or referral forms; on-site point of care (POC) CD4 testing immediately after testing HIV positive; patient education; and SMS reminders. Studies show that individuals who receive POC CD4 testing at the time of testing HIV positive are more likely to link to care than those with standard CD4 testing.^{12,13}

Cotrimoxazole prophylaxis for all eligible PLHIV

Cotrimoxazole should be provided to all eligible individuals as per national guidelines, including HIV-exposed and -infected infants and children, adolescents, pregnant women and other adults living with HIV.

Cotrimoxazole, a fixed dose combination of trimethoprim and sulfamethoxazole, has activity against a range of bacteria as well as fungi and protozoa. Cotrimoxazole prevents *Pneumocystis jirovecii* pneumonia and toxoplasmosis in PLHIV, and has also been shown to prevent malaria and some bacterial infections in certain settings. The standard dose of cotrimoxazole in adults is one double-strength tablet (or two single-strength tablets) once daily; age-based dosing is used for infants and children (see dosing charts on the [Clinical & Training Unit WIKI](#)). Cotrimoxazole prophylaxis has been shown to have both mortality¹⁴⁻¹⁶ and morbidity¹⁷⁻¹⁹ benefits in PLHIV.

TB screening

Adults living with HIV should be screened for TB at regular intervals as per national guidelines, using a symptom-based questionnaire consisting of current cough, fever, weight loss, and night sweats.

Children >12 months of age living with HIV should be screened for TB at regular intervals as per national guidelines, using a questionnaire consisting of poor weight gain, fever, current cough and contact history with a TB case.²⁰

For those with a positive screen, further diagnostic work-up and treatment

Individuals with a positive screen should be evaluated for TB as per national guidelines, given that PLHIV with TB have a high mortality risk.^{21,22} Xpert MTB/RIF should be the initial diagnostic test where available; it has greater sensitivity than smear microscopy, and also detects rifampicin resistance.²³

PLHIV who are diagnosed with TB should be started on TB treatment promptly, and then initiated on ART within two-four weeks of TB treatment initiation, regardless of CD4 count.²⁴

TB is the most common opportunistic illness and leading cause of death among PLHIV. Early TB case detection improves patient outcomes²⁵ and decreases the risk of TB transmission in health care settings, households and communities.²⁵⁻²⁷ Clinical trial data demonstrate that initiating ART early during TB treatment greatly increases AIDS-free survival.²⁸⁻³¹

Strategies to improve early ART initiation among PLHIV with TB include: provision of ART at TB clinics, and provision of TB treatment in HIV clinics.

For those with a negative screen and/or diagnostic work-up, isoniazid preventive therapy

Isoniazid should be given for at least six months to all PLHIV (including children >1 year, pregnant women, and other adults based on national guidelines) with a negative screen and/or diagnostic work-up for TB, regardless of CD4 count, previous TB treatment, or ART status.

There is a substantial amount of evidence showing that isoniazid preventive therapy (IPT) decreases TB incidence.³²⁻⁴⁰ Some,^{35,41-43} but not all,^{32-34,36,44-47} studies have also demonstrated a mortality benefit from IPT.

Assessment of ART eligibility, with prompt ART initiation for all eligible patients

PLHIV should be assessed for ART eligibility and initiated on ART promptly when found to be eligible as per national guidelines.

ART eligibility criteria vary by country and may include pregnancy, comorbid conditions (e.g., TB), serodiscordant couples, and age groups (e.g., children under 5 years of age), as well as WHO stage and CD4 cut-points.

Delays in ART initiation lead to greater mortality, faster disease progression, ongoing HIV transmission, and often incomplete immune restoration.⁴⁸⁻⁵²

Programs may use strategies such as job aids to assist health care workers with clinical staging and determining ART eligibility or chart review to ensure that eligible patients are initiated on ART promptly.

WHO staging at every visit, including assessment and treatment for opportunistic illnesses

An interim history and physical exam, including assessment of weight, height, and WHO stage, should be performed for all patients at each clinical visit. WHO stage should be recorded and used to determine ART eligibility.

For all children, documentation of growth and developmental assessment should be included in the patient file, and for those <2 years of age, head circumference should be measured and recorded.

Findings suggestive of OIs should prompt further diagnosis and management as per national guidelines.

CD4 testing at enrollment in care and every six months thereafter

CD4 testing should be performed within one month of enrollment into care, ideally at the time of HIV diagnosis. CD4 testing should then be repeated at six month intervals. Results should be reviewed, documented in care files, and used for management according to national guidelines.

CD4 cell count is highly predictive of disease progression and survival, and thus is routinely used as a prognostic indicator^{48,53} and to assess ART eligibility in PLHIV.

Prevention of mother-to-child transmission of HIV

There are several components of preventing HIV transmission from mother-to-child including: primary prevention of HIV in women of childbearing age; prevention of unintended pregnancies in women living with HIV; provision of ART for all pregnant and breastfeeding women with HIV infection; and ongoing care of mothers and infants.

Family planning services to prevent unintended pregnancies in women with HIV

Family planning services should either be integrated into HIV care or available through facilitated linkage to family planning clinics.

Prevention of unplanned pregnancies in women living with HIV is critical for reducing perinatal HIV transmission. A study in Kenya demonstrated that a combination approach including free contraceptive provision on-site at an HIV research clinic, as well as contraceptive promotion and counseling, led to increased uptake of contraceptives and decreased pregnancy incidence.⁵⁴

Provision of ART for all pregnant and breastfeeding women with HIV infection, with a preference for option B+, and ongoing care for HIV-infected mothers and exposed infants

ART should be provided to HIV-infected pregnant and breastfeeding women in all maternal and child health service delivery points (including antenatal care settings, reproductive and child health programs and maternity), to reduce the risk of mother-to-child transmission and maternal morbidity and mortality.

Ideally, all HIV-positive pregnant and breastfeeding women should be started on once-daily triple drug therapy,⁵⁵⁻⁵⁷ in line with the recommended efavirenz-based first-line regimen for non-pregnant adults and adolescents. Preferably, this regimen should be continued for life (Option B+),⁵⁸⁻⁶¹ or at least until cessation of breastfeeding in women who do not meet ART eligibility criteria (Option B).^{62,63}

Infants should receive ARV prophylaxis at birth, with provision of ongoing care for mothers and infants during breastfeeding and until the infant's final HIV infection status is determined.

The Option B+ approach harmonizes treatment for pregnant and breastfeeding women with that recommended for other adults and adolescents. It also assures that all women eligible for treatment start ART for their own health, while providing additional benefits including preventing mother-to-child transmission in future pregnancies as well as reducing the risk of sexual transmission in serodiscordant couples.

Monitoring medication adherence, side effects, and treatment response

PLHIV on medications including ART, cotrimoxazole, and IPT should be monitored for adherence, side effects and treatment response, with provision of adherence support and management of toxicity and treatment failure.

Monitoring and supporting adherence

Adherence should be assessed at every clinical visit, and ideally also at the time of pharmacy refills, in all PLHIV on ART and/or other medications, including cotrimoxazole and IPT. If possible, drug pick-ups should also be monitored, to identify individuals at high risk for inadequate adherence. A standardized method to assess and record adherence should be devised and implemented.

One commonly-used method for assessing adherence is to ask patients about the number of missed doses in the prior week and the prior month. It is also helpful to ask about reasons for missed doses, in order to provide advice on strategies to improve adherence. Adherence can be assessed by care providers, pharmacists, peer counselors, or other cadres; the person responsible for assessing adherence should be specified and should use the accepted approach for assessment to ensure that it is routinely performed and documented. Monitoring drug pick-ups is also helpful to identify patients at high risk for inadequate adherence, so that they can be targeted for adherence support.

Poor adherence to ART predicts disease progression,⁶⁴ emergence of drug-resistance mutations⁶⁵ and treatment failure.⁶⁶ Reviews on adherence support have shown that adherence counseling, as well as other interventions including food supplementation in food-insecure individuals,⁶⁷ SMS text messages^{68,69} and directly observed therapy with community health workers⁷⁰ can improve self-reported adherence and virologic suppression.⁷¹⁻⁷⁴

Monitoring for side effects and managing toxicity

All PLHIV on ART or other medications including cotrimoxazole and IPT should be assessed for side effects at every visit, through both history-taking and a targeted physical exam.

Individuals suspected of medication toxicity should be managed as per national algorithms, including referral for consultation and/or laboratory tests as indicated.

Monitoring for treatment response and management of treatment failure

Patients on ART should be regularly evaluated for treatment response using laboratory (viral load or CD4 testing) criteria, or if not available, clinical (WHO staging) criteria.

After six months of ART, patients should be monitored for treatment response with viral load if available or if not, with CD4 and/or clinical criteria. Viral load monitoring has better sensitivity and positive predictive value for detecting treatment failure than clinical or immunologic monitoring,⁷⁵⁻⁸⁰ and is recommended as the preferred method of monitoring PLHIV on ART in the 2013 WHO guidelines.²⁴ However, many programs do not have access to viral load testing, in which case immunologic and/or clinical criteria for pediatric and adult populations as per national guidelines should be used to detect, as well as manage, treatment failure.

Monitoring and supporting retention in care

Implementation of an appointment system and a method to track PLHIV enrolled in care, as well as interventions to support retention, should be implemented to minimize loss to follow up.

HIV is a chronic disease necessitating lifelong care, thus appointment systems are essential for ensuring that patients receive regular follow-up and health care workers are able to track and support patient retention. Extra attention may be needed for those at high risk of loss to follow up, including men, younger adults, and those not eligible for ART. Studies have shown that mortality is high among PLHIV not retained in care.⁸¹⁻⁸³

A number of strategies can be employed to support retention in care. A study in Kenya showed that providing free cotrimoxazole to PLHIV ineligible for ART increased retention.⁸⁴ Utilization of community-based groups of patients for ART refills and adherence assessments has also been shown to increase retention.⁸⁵ SMS text messaging has been shown to improve attendance in some outpatient settings,^{86,87} and is currently being studied specifically for HIV care.

Access to laboratory testing

Access to quality-assured laboratory tests along the continuum of care is vital, either through onsite capacity building or establishment of specimen transport systems. These include: HIV diagnostic services such as rapid HIV testing and DBS-based DNA PCR testing for EID; monitoring tests including CD4 testing and in some settings, HIV viral load; and access to smear microscopy and/or Xpert MTB/RIF for all PLHIV enrolled in care.

Psychosocial Support

Psychosocial support is essential to all areas of HIV care and should be integrated into the above Core Interventions.

Some programs use peer educators, expert clients, volunteer health workers, or support groups as a means of supporting patients, particularly in areas such as adjusting to an HIV diagnosis, linking to care, adhering to ART, and remaining in care.

Appendix

Following are examples of SOPs and tools to support implementation of core interventions in the ICAP Package of Care.

SOPs and Tools to Support Implementation of Core Interventions in the ICAP Package of Care*
HIV Testing & Counseling
SOP for PITC (generic)
Family Testing Form (Ethiopia)
Family and Partner Testing Cue Card (generic)
Linkage to Care
SOP for Linkage and Retention (Swaziland)
Linkage Job Aid (Kenya)
Cotrimoxazole Prophylaxis
Cotrimoxazole Job Aid (Ethiopia)
TB Screening
TB Screening and IPT Forms - infants, children, and adults (Ethiopia)
Assessment of ART Eligibility
ART Eligibility Checklist (Swaziland)
Preventing Mother-to-Child Transmission
Family Planning Screening Tool (generic)
Family Planning Site Assessment Tool (generic)
Option B+ Flow Charts - ANC, labor & delivery, breastfeeding (Ethiopia)
PMTCT Counseling Flip Chart (generic)
B+ Retention Monitoring Tool (generic)
Monitoring Adherence, Side Effects, Treatment Response
5 Steps for PLHIV Job Aid (Ethiopia)
Retention in Care
SOP for Linkage and Retention (Swaziland)
Laboratory Testing
Dried Blood Spot SOP (Ethiopia)
Dried Blood Spot Result Tracking Tool (Tanzania)

*These are examples and may require adaptation to reflect the most recent national guidelines

References

1. Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. *AIDS Behav.* May 2011;15(4):751-760.
2. Roura M, Watson-Jones D, Kahawita TM, Ferguson L, Ross DA. Provider-initiated testing and counselling programmes in sub-Saharan Africa: a systematic review of their operational implementation. *AIDS.* Feb 20 2013;27(4):617-626.
3. Conkling M, Shutes EL, Karita E, et al. Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study. *J Int AIDS Soc.* 2010;13:10.
4. Farquhar C, Kiarie JN, Richardson BA, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. *J Acquir Immune Defic Syndr.* Dec 15 2004;37(5):1620-1626.
5. Kalembo FW, Zgambo M, Mulaga AN, Yukai D, Ahmed NI. Association between male partner involvement and the uptake of prevention of mother-to-child transmission of HIV (PMTCT) interventions in Mwanza district, Malawi: a retrospective cohort study. *PLoS One.* 2013;8(6):e66517.
6. Msuya SE, Mbizvo EM, Hussain A, Uriyo J, Sam NE, Stray-Pedersen B. Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs. *AIDS Care.* Jul 2008;20(6):700-709.
7. Aluisio A, Richardson BA, Bosire R, John-Stewart G, Mbori-Ngacha D, Farquhar C. Male antenatal attendance and HIV testing are associated with decreased infant HIV infection and increased HIV-free survival. *J Acquir Immune Defic Syndr.* Jan 1 2011;56(1):76-82.
8. Becker S, Mlay R, Schwandt HM, Lyamuya E. Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial. *AIDS Behav.* Jun 2010;14(3):558-566.
9. WHO. Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. 2012.
10. Semrau K, Kuhn L, Vwalika C, et al. Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events. *AIDS.* Mar 24 2005;19(6):603-609.
11. Tonwe-Gold B, Ekouevi DK, Bosse CA, et al. Implementing family-focused HIV care and treatment: the first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Cote d'Ivoire. *Trop Med Int Health.* Feb 2009;14(2):204-212.
12. Faal M, Naidoo N, Glencross DK, Venter WD, Osih R. Providing immediate CD4 count results at HIV testing improves ART initiation. *J Acquir Immune Defic Syndr.* Nov 1 2011;58(3):e54-59.
13. Larson BA, Schnippel K, Ndibongo B, et al. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa. *J Acquir Immune Defic Syndr.* Oct 1 2012;61(2):e13-17.
14. Wiktor SZ, Sassin-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. *Lancet.* May 1 1999;353(9163):1469-1475.
15. Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. *Bull World Health Organ.* Feb 1 2012;90(2):128C-138C.
16. Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. *AIDS.* Jul 17 2010;24(11):1709-1716.
17. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. *Lancet.* May 1 1999;353(9163):1463-1468.
18. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. *Lancet.* Apr 10 2010;375(9722):1278-1286.

19. Campbell JD, Moore D, Degerman R, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/muL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. *Clin Infect Dis*. Apr 2012;54(8):1204-1211.
20. WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children, second edition. 2014.
21. Cain KP, Kanara N, Laserson KF, et al. The epidemiology of HIV-associated tuberculosis in rural Cambodia. *Int J Tuberc Lung Dis*. Sep 2007;11(9):1008-1013.
22. Lopez-Gatell H, Cole SR, Margolick JB, et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. *AIDS*. Sep 12 2008;22(14):1869-1873.
23. WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children, policy update. 2013.
24. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013.
25. Currie CS, Williams BG, Cheng RC, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? *AIDS*. Nov 21 2003;17(17):2501-2508.
26. Burgess AL, Fitzgerald DW, Severe P, et al. Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. *AIDS*. Sep 28 2001;15(14):1875-1879.
27. WHO. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. 1999.
28. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. *N Engl J Med*. Oct 20 2011;365(16):1492-1501.
29. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med*. Oct 20 2011;365(16):1482-1491.
30. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med*. Oct 20 2011;365(16):1471-1481.
31. Violarì A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. *N Engl J Med*. Nov 20 2008;359(21):2233-2244.
32. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Jr., Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. *Lancet*. Oct 28 2000;356(9240):1470-1474.
33. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. *AIDS*. Dec 24 1998;12(18):2447-2457.
34. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. *N Engl J Med*. Sep 18 1997;337(12):801-808.
35. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. *AIDS*. Nov 9 2001;15(16):2129-2135.
36. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. *AIDS*. Jan 26 2001;15(2):215-222.
37. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? *AIDS*. Sep 26 2003;17(14):2063-2070.
38. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. *AIDS*. Mar 13 2009;23(5):631-636.
39. Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, et al. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. *AIDS Res Hum Retroviruses*. Mar 2012;28(3):270-275.
40. Kibret KT, Yalew AW, Belaineh BG, Asres MM. Determinant factors associated with occurrence of tuberculosis among adult people living with HIV after antiretroviral treatment initiation in Addis Ababa, Ethiopia: a case control study. *PLoS One*. 2013;8(5):e64488.

41. Kabali C, von Reyn CF, Brooks DR, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. *Int J Tuberc Lung Dis*. Nov 2011;15(11):1515-1521, i.
42. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. *BMJ*. Sep 5 1998;317(7159):625-629.
43. Charalambous S, Grant AD, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. *AIDS*. Nov 2010;24 Suppl 5:S5-13.
44. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. *AIDS*. Jun 1997;11(7):875-882.
45. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. *AIDS*. Nov 9 2001;15(16):2137-2147.
46. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. *Int J Tuberc Lung Dis*. Oct 2007;11(10):1114-1120.
47. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. *Cochrane Database Syst Rev*. 2010(1):CD000171.
48. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. Jul 13 2002;360(9327):119-129.
49. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet*. Mar 11 2006;367(9513):817-824.
50. Strategies for Management of Antiretroviral Therapy Study G, Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. *J Infect Dis*. Apr 15 2008;197(8):1133-1144.
51. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. Apr 30 2009;360(18):1815-1826.
52. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. *N Engl J Med*. Jul 15 2010;363(3):257-265.
53. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med*. Jun 15 1997;126(12):946-954.
54. Ngure K, Heffron R, Mugo N, Irungu E, Celum C, Baeten JM. Successful increase in contraceptive uptake among Kenyan HIV-1-serodiscordant couples enrolled in an HIV-1 prevention trial. *AIDS*. Nov 2009;23 Suppl 1:S89-95.
55. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. Aug 11 2011;365(6):493-505.
56. Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. *Curr Opin HIV AIDS*. Sep 2013;8(5):474-489.
57. Chibwesha CJ, Giganti MJ, Putta N, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. *J Acquir Immune Defic Syndr*. Oct 1 2011;58(2):224-228.
58. Kesho Bora Study G. Maternal HIV-1 disease progression 18-24 months postdelivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): The Kesho Bora randomized controlled trial. *Clin Infect Dis*. Aug 2012;55(3):449-460.
59. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med*. Jun 17 2010;362(24):2271-2281.
60. Jamieson DJ, Chasela CS, Hudgens MG, et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. *Lancet*. Jun 30 2012;379(9835):2449-2458.

61. McIntyre J. Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries. *Curr Opin HIV AIDS*. Jan 2010;5(1):48-53.
62. WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: programmatic update. 2012.
63. Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women MaC. Toolkit-Expanding and simplifying treatment for pregnant women living with HIV: managing the transition to option B/B+. 2013; <http://www.emtct-iatt.org/toolkit/>.
64. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. *AIDS*. Jun 15 2001;15(9):1181-1183.
65. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. *J Infect Dis*. Feb 1 2005;191(3):339-347.
66. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. *Clin Infect Dis*. Apr 15 2002;34(8):1115-1121.
67. Cantrell RA, Sinkala M, Megazinni K, et al. A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia. *J Acquir Immune Defic Syndr*. Oct 1 2008;49(2):190-195.
68. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WeTel Kenya1): a randomised trial. *Lancet*. Nov 27 2010;376(9755):1838-1845.
69. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS*. Mar 27 2011;25(6):825-834.
70. Munoz M, Finnegan K, Zeladita J, et al. Community-based DOT-HAART accompaniment in an urban resource-poor setting. *AIDS Behav*. Jun 2010;14(3):721-730.
71. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. *J Acquir Immune Defic Syndr*. Mar 2006;41(3):285-297.
72. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. *J Acquir Immune Defic Syndr*. Dec 1 2006;43 Suppl 1:S23-35.
73. Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. *Lancet Infect Dis*. Dec 2011;11(12):942-951.
74. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. *Cochrane Database Syst Rev*. 2006(3):CD001442.
75. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. *BMJ*. 2011;343:d6792.
76. Jourdain G, Le Coeur S, Ngo-Giang-Huong N, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. *PLoS Med*. Aug 2013;10(8):e1001494.
77. Saag MS ea. A cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia. . 19th Annual Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA, USA.
78. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. *J Acquir Immune Defic Syndr*. Sep 1 2011;58(1):23-31.
79. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. *Clin Infect Dis*. Aug 1 2009;49(3):454-462.

80. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. *Clin Infect Dis*. Dec 2011;53(12):1283-1290.
81. Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. *J Acquir Immune Defic Syndr*. Jan 1 2008;47(1):101-107.
82. Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. *Bull World Health Organ*. Jul 2007;85(7):550-554.
83. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. *AIDS*. Oct 1 2008;22(15):1897-1908.
84. Kohler PK, Chung MH, McGrath CJ, Benki-Nugent SF, Thiga JW, John-Stewart GC. Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. *AIDS*. Aug 24 2011;25(13):1657-1661.
85. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. *J Acquir Immune Defic Syndr*. Feb 1 2011;56(2):e39-44.
86. Downer SR, Meara JG, Da Costa AC, Sethuraman K. SMS text messaging improves outpatient attendance. *Aust Health Rev*. Aug 2006;30(3):389-396.
87. Liew SM, Tong SF, Lee VK, Ng CJ, Leong KC, Teng CL. Text messaging reminders to reduce non-attendance in chronic disease follow-up: a clinical trial. *Br J Gen Pract*. Dec 2009;59(569):916-920.